Free Trial

Biodesix (BDSX) Stock Price, News & Analysis

Biodesix logo
$0.43 -0.02 (-4.44%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$0.45 +0.02 (+5.72%)
As of 08/29/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Biodesix Stock (NASDAQ:BDSX)

Key Stats

Today's Range
$0.42
$0.46
50-Day Range
$0.25
$0.49
52-Week Range
$0.17
$2.04
Volume
5.23 million shs
Average Volume
1.22 million shs
Market Capitalization
$62.55 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.75
Consensus Rating
Moderate Buy

Company Overview

Biodesix Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
70th Percentile Overall Score

BDSX MarketRank™: 

Biodesix scored higher than 70% of companies evaluated by MarketBeat, and ranked 301st out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Biodesix has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Biodesix has received no research coverage in the past 90 days.

  • Read more about Biodesix's stock forecast and price target.
  • Earnings Growth

    Earnings for Biodesix are expected to grow in the coming year, from ($0.35) to ($0.24) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Biodesix is -1.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Biodesix is -1.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Biodesix has a P/B Ratio of 42.66. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Biodesix's valuation and earnings.
  • Percentage of Shares Shorted

    3.82% of the float of Biodesix has been sold short.
  • Short Interest Ratio / Days to Cover

    Biodesix has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Biodesix has recently decreased by 8.41%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Biodesix does not currently pay a dividend.

  • Dividend Growth

    Biodesix does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.82% of the float of Biodesix has been sold short.
  • Short Interest Ratio / Days to Cover

    Biodesix has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Biodesix has recently decreased by 8.41%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Biodesix has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.09 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Biodesix this week, compared to 1 article on an average week.
  • Search Interest

    10 people have searched for BDSX on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Biodesix insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,481.00 in company stock.

  • Percentage Held by Insiders

    30.10% of the stock of Biodesix is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 20.96% of the stock of Biodesix is held by institutions.

  • Read more about Biodesix's insider trading history.
Receive BDSX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biodesix and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BDSX Stock News Headlines

Biodesix, Inc. (BDSX) Q2 2025 Earnings Call Transcript
This is my Christian duty
“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 trillion vault of untapped American wealth. Former CIA advisor Jim Rickards calls it the “Old Testament Wealth Code” — and says it could transform your financial future. He’s revealing everything in a new presentation.tc pixel
See More Headlines

BDSX Stock Analysis - Frequently Asked Questions

Biodesix's stock was trading at $1.53 on January 1st, 2025. Since then, BDSX stock has decreased by 72.1% and is now trading at $0.4266.

Biodesix, Inc. (NASDAQ:BDSX) issued its quarterly earnings results on Thursday, August, 7th. The company reported ($0.08) EPS for the quarter, missing analysts' consensus estimates of ($0.07) by $0.01. The business earned $20.02 million during the quarter, compared to analyst estimates of $18.47 million. Biodesix had a negative net margin of 53.66% and a negative trailing twelve-month return on equity of 269.67%.
Read the conference call transcript
.

Biodesix (BDSX) raised $76 million in an initial public offering on Wednesday, October 28th 2020. The company issued 4,200,000 shares at a price of $17.00-$19.00 per share. Morgan Stanley and William Blair acted as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers.

Biodesix's top institutional shareholders include Geode Capital Management LLC (0.51%), Shay Capital LLC (0.16%) and XTX Topco Ltd (0.14%). Insiders that own company stock include Jack W Schuler, John Patience, Scott Hutton, Robin Harper Cowie, Gary Anthony Pestano, Kieran O'kane and Chris Vazquez.
View institutional ownership trends
.

Shares of BDSX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Biodesix investors own include Broadcom (AVGO), NVIDIA (NVDA), Adobe (ADBE), Arista Networks (ANET), ServiceNow (NOW), CrowdStrike (CRWD) and Meta Platforms (META).

Company Calendar

Last Earnings
8/07/2025
Today
8/30/2025
Next Earnings (Estimated)
11/07/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Medical Services
Sub-Industry
Healthcare
Current Symbol
NASDAQ:BDSX
CIK
1439725
Fax
N/A
Employees
220
Year Founded
N/A

Price Target and Rating

High Price Target
$2.00
Low Price Target
$1.50
Potential Upside/Downside
+310.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.29)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$42.93 million
Net Margins
-53.66%
Pretax Margin
-53.66%
Return on Equity
-269.67%
Return on Assets
-43.94%

Debt

Debt-to-Equity Ratio
41.11
Current Ratio
2.14
Quick Ratio
2.14

Sales & Book Value

Annual Sales
$71.32 million
Price / Sales
0.88
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.01 per share
Price / Book
42.66

Miscellaneous

Outstanding Shares
146,630,000
Free Float
102,496,000
Market Cap
$62.55 million
Optionable
Optionable
Beta
0.99

Social Links

7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

This page (NASDAQ:BDSX) was last updated on 8/31/2025 by MarketBeat.com Staff
From Our Partners